Cornea

The authors emphasised that consumers and clinicians should be made aware of potential ophthalmic adverse events associated with cosmetics and personal care products

A qualitative study method illuminates patients’ fears for the future

A case report highlights the pathogen’s potential to cause severe, devastating ocular infections, despite aggressive treatment

Highlights from the year, courtesy of our colleagues at Ophthalmology Times

Trending topics and milestone stories from our year in ophthalmology

Our top 10 print stories highlight the core content concepts we explored this year

Low-level light therapy for dry eye disease and chalazion

Espansione Group's Light Modulation Low-level Light Therapy (LLLT) is used in ophthalmology and dermatology

The authors analysed severity and frequency of ocular pain among patients with DED living in altitudes above 2,500 meters during the COVID-19 pandemic

The incidence was comparable to that of daily wear soft contact lenses

Assessing two devices in a real-world setting

Investigators from Bergen, Norway, and Cleveland, Ohio, collaborated on the predictive model

Research indicates suppressive valacyclovir could help patients avoid keratitis and iritis flare-ups

The authors reported significant variability in DED-related symptoms, with higher prevalence rates among university students and administrative workers

Farhad Hafezi, FARVO, MD, PhD, and colleagues reported on results achieved with phototherapeutic keratectomy-assisted, customised, epi-on corneal crosslinking

Dry eye increases susceptibility to psychiatric disorders and chronic pain syndromes, investigators reported at the 2024 AAO meeting

Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease

Current and future options for Fuchs endothelial corneal dystrophy

Neltependocel has received both regulatory and reimbursement approval in Japan

Michael Goldstein, MD, discusses 12-month safety and efficacy trial data of human corneal endothelial cell therapy, presented at the 2024 ESCRS Congress

Phase 1 multicentre study data demonstrate early signs of efficacy

Akantior, an anti-amoebic polymer eye drop, is the first and only authorised medical product for the treatment of AK in the world, according to a news release.

European patients navigate new therapies and market change-ups

Specular microscopy showed "long-term alterations" in corneal cells

The positive opinion comes with the recommendation that ciclosporin 0.1% be granted marketing authorisation in the European Union